Nutcracker Therapeutics Stock

nutcrackerx.comHealthcare / BioTech & PharmaFounded: 2017Funding to Date: $243.3MM

Nutcracker Therapeutics develops a platform to enable the development and manufacturing of all RNA therapeutics.

Register To Buy and Sell Shares

For more details on financing and valuation for Nutcracker Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Nutcracker Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Nutcracker Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Frequently Asked Questions About Nutcracker Therapeutics’ Stock

plusminus
Can you buy Nutcracker Therapeutics’ stock?
Nutcracker Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Nutcracker Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Nutcracker Therapeutics’ stock?
Yes, you can sell stock of a private company like Nutcracker Therapeutics. Forge can help you sell your Nutcracker Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Nutcracker Therapeutics’ stock price?
Nutcracker Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Nutcracker Therapeutics’ private market stock price with Forge Data.
plusminus
What is Nutcracker Therapeutics’ stock ticker symbol?
Nutcracker Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Why RNA Is Good For Business
Nutcracker Therapeutics raised $170 million in a Series C funding round to continue developing its RNA drug development platform. The company's preclinical lineup includes a multimodal RNA therapeutic for HPV-driven tumors, a patient-specific multimodal RNA therapeutic for T cell lymphoma, and a multimodal RNA therapeutic for genitourinary tumors. The company's in-house RNA production capability aids in eliminating common bottlenecks at the research and discovery stages, providing a cost-efficient platform for the screening of different protein constructs.
Nutcracker Therapeutics appoints Cynthia Collins, biopharma veteran and former Editas Medicine CEO, to board of directors
Nutcracker Therapeutics has appointed Cynthia Collins, a biopharma veteran and former CEO of Editas Medicine, to its board of directors. Collins brings over four decades of experience in the pharmaceutical and biotech industry and is currently the lead director at Panavance Therapeutics Inc. Her expertise in oncology, cell and gene therapies, and CRISPR will be crucial as Nutcracker Therapeutics prepares for its first clinical trial with lead candidate, NTX-250.
Updated on: Apr 15, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.